Pharmacogenetics of oral antidiabetic treatment

Bratislava Medical Journal

Volumn 112, Issue 8, 2011, Pages 441-446

  Schroner, Z ^a   Javorsky, M ^a   Kozarova, M ^a   Tkac, I ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Diabetes mellitus type 2; Oral antidiabetic drugs; Pharmacogenetics

Indexed keywords

EID: 80052149248     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Barroso I. Genetics of type 2 diabetes. Diabet Med 2005; 22: 517535.
2. Lyssenko V et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359: 2220-2232.
3. Dobríková M, Stančáková A, Javorský M, Tkáč I. Genetic background of type 2 diabetes mellitus. Interna med 2007; 3: 147-152.
4. Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-894.
5. Lyssenko V. The transcription factor-7 like 2 gene and increased risk of type 2 diabetes: an update. Curr Opin Nutr Metab Care 2008; 1: 385-392.
6. Reis AF, Velho G. Sulfonylurea receptor -1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus. Diabetes Metab 2002; 28: 14-19.
7. Van Dam RM, Hoebee B, Seidell JC et al. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population -based studies and meta-analyses. Diabetes UK. Diabetic Medicine 2005; 2: 590-598.
8. Yasuda K, Miyake K, Horikawa Y et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40 (9): 1092-1097.
9. Lyssenko V, Nagorny CLF, Erdos MR et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2008; DOI: 10.1038/ng.208.
10. Steinthorsdottir V et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39: 770-775.
11. Tkáč I. Enhancement of incretin effect as a new therapeutic approach it the treatment of tpye 2 diabetes mellitus. Intern Med 2006; 12: 668-671.
12. Baron AD. Postprandial hyperglycaemia and alpha - glucosidase inhibitors. Diabetes Res Clin Pract 1998; 40: Suppl 1: 51-55.
13. Bozkurt O, De Boer A, Grobbee DE et al. Pharmacogenetics of glucose-lowering drug treatment. Mol Diag Ther 2007; 11: 291-302.
14. Gribble FM, Reimann, F. Sulphonylurea action revisited: the post cloning era. Diabetologia 2003; 46: 875-891.
15. Reis AF, Velho G. Sulfonylurea receptor-1 ( SUR 1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus. Diabetes Metab 2002; 28, 14: 14-19.
16. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) nad SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52 (2): 568-572.
17. Vaxillaire M, Populaire C, Busiah K et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in large cohort of French patients. Diabetes 2004; 53: 2719-2722.
18. Staník J, Gašperíková D, Pašková M et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and BCC8 mutation carriers. JCEM 2007; 4.
19. Zychma MJ, Gumprecht J, Strojek K et al. Sulfonylurea receptor gene 16-3 polymorphism -association with sulfonylurea or insulin treatment in type 2 diabetes subjects. Med Sci Monit 2002; 8-7: 512-515.
20. Meirhaeghe A, Helbecque N, Cottel D et al. Impact of sulfonylu-rea receptor 1 genetic variability on non-insulin dependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet 2001; 101 (1): 4-8.
21. Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of glicla-zide in Chinese type 2 diabetic patients. Diabetes Care 2008; 31: 19391944.
22. Zhang H, Liu X, Kuang H et al. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Research and Clinical Practice 2007; 77: 58-61.
23. Sesti G, Laratta E, Cardellini M et al. The E23K variant of KCN11 endcoding the pancreatic beta-cell adenosine 5 triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylureas in patients with type 2 diabetes. J. Clin Endocrinol Metab 2006; 91: 2334-2339.
24. Holstein A, Hahn M, Stumvoll M et al. The E23K viariant of KCN11 and the risk for severe sulfonylurea -induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 2009; DOI 10.1055/s-0029-1192019.
25. Smith U. TCF7L2 and type 2 diabetes - we WNT to know. Diabetologia 2007; 50: 5-7.
26. Hattersley AT. Prime suspect: the TCF7L2 gene and type 2 diabetes risk. J Clin Invest 2007; 17: 2178-236.
27. Pearson ER, Donelly LA, Kimber CH et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas. AGoDARTs Study. Diabetes 2007; 56: 2178-2182.
28. Shepherd M, Pearson ER, Houghton J et al. No deterioration in glycemic control in HNF-1 alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003; 26 (1): 3191-3192.
29. Becker ML, Aarnoudse AJLHJ, Newton-Cheh CH et al. Common variation in the NOS1AP genes is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylu-rea. Pharmacogenetics and Genomics 2008; 18: 591-597.
30. Sesti G, Marini MA, Cardellini M et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004; 27 (6): 1394-1398.
31. Becker ML, Visser LE, Trienekens PH et al. Cytochrome P4502C9 (*)2 and (*)3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes melitus. Clin Pharmacol Ther 2007.
32. Suzuki K, Yanagava T, Shibasaki T et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Research and Clinical Practice 2006; 72: 148-154.
33. Holstein A, Plaschke A, Ptak M et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycemic agents. Br J Clin Pharmacol 2005; 60 (1): 103-106.
34. Moorodian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999; 57 (1): 19-29.
35. Niemi M, Leathart JB, Neuvonen M et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74 (4): 380-387.
36. Niemi M, Backman JT, Kajosaari LE et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77 (6): 468-478.
37. Drucker DJ, Nauck MA. The incretin system: glucagon-like pepti-de-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
38. Bouatia-Naji N, Bonnenfond A, Cavalcanti-Proenca Ch et al. A variant near MTNR1B is associated with the increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2008; DOI:10.1038/ng.277.
39. Beinborn M, Worall CHI, McBride EW et al. A human gluca-gon-like peptide receptor polymorphism results in reduced agonist responsiveness. Regulatory Peptides 2005, 130: 1-6.
40. Tokuyama, Y, Matsui K, Egashira T et al. Five misssence mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 2004; 66: 63-69.
41. Hawley SA, Gadalla AE, Olsen GS et al. The antidiabetic drug metfor-min activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51: 2420-2425.
42. Ertrunc D, Tok EC, Aktas A. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Human Reproduction 2005; 20: 1207-1212.
43. Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-1646.
44. Legro RS, Barnhart HX, Schlaff WD et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008; 93: 792-800.
45. Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1(OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
46. Shikata E, Yamamoto R, Takane H et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007; 52: 117-122.
47. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131 (4): 281-303.
48. Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous peroxisome proliferaton receptor g (PPARg) deficiency and PPARg agonists improve insulin resistance. The Journal of biological Chemistry 2001; 276 (44): 41245-41254.
49. Kang ES, Park SY, Kim HJ et al. Effects of Pro12Ala polymorphism of peroxisome proliferator -activated receptor gamma 2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 78, 2: 202-208.
50. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor g in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000; 20: 1868-1876.
51. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
52. Kang ES, Park SY, Kim HJ et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005; 28 (5): 1139-1144.
53. Mottugai-Tabar S, Ryden M, Lofgren P et al. Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis. Diabetologia 2003; 46: 789-797.
54. Kang ES, Cha SB, Kim HJ et al. The 11482G>A polymorhism in the perilipin genes is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care 2006; 29: 1320-1324.
55. Javorsky M, Kozárová M, Šalagovič J, Tkáč I. Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients. Physiol Res 2006; 55: 55-62.
56. Wang G, Wang X, Zhang Q et al. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract 2007; 61: 552-557.
57. Andrulionyte L, Zacharova J, Chiasson JL et al. Common poly-morhisms of the PPAR-gamma 2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucoese tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004; 47: 2176-2184.
58. Zacharova J, Chiasson JL, Laakso M. The common polymorphisms (single nucleotid polymorphism /SNP/+45 and SNP+276) of the adi-ponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes:the STOP-NIDDM trial. Diabetes 2005; 54: 893-899.